Ways Healthcare Differs Depending on the State an Immigrant Child Resides In | ATS 2024
May 22nd 2024Undocumented individuals are ineligible for the Affordable Care Act (ACA) or federally funded Medicaid, but some states offer state-sponsored coverage for certain immigration statuses, such as Temporary Protected Status.
Read More
The American Thoracic Society (ATS) has recommended moving to race-neutral equations for assessing what lung functions mean. A study presented at the ATS meeting this weekend projected how the new equation would affect disease classification, lung test standards for becoming a firefighter and VA disability benefits.
Read More
Tezspire's Effect on COPD Exacerbations May Hinge on Blood Eosinophil Counts | 2024 ATS
May 21st 2024Results from a phase 2a study suggest that the benefits of Tezspire (tezepelumab) for people with chronic pulmonary obstructive disease may be limited to those with elevated blood eosinophil counts indicative of type 2 inflammation.
Read More
The Role of Pharmacogenomics in Reducing Racial Disparities in Pediatric AML Treatment Outcomes
May 20th 2024A new study in JAMA Network Open suggests that disparities in outcomes between Black and White children with acute myeloid leukemia may be due to differences in pharmacogenomics, which is how genes affect drug responses.
Read More
More Good News About Dupixent for COPD Subgroup With Type 2 Inflammation | 2024 ATS
Published: May 20th 2024 | Updated: May 20th 2024Results from the phase 3 NOTUS trial presented at the ATS meeting confirm benefits of Dupixent (dupilumab) among 20% to 40% of people with chronic obstructive pulmonary disease (COPD) who have evidence of type 2 inflammation.
Read More
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Dr. Glaucomflecken the Opening Speaker Today at the 2024 ATS Meeting | 2024 ATS
May 18th 2024William Flanary, M.D.., has a huge social media following as Dr. Glaucomflecken, a character he created on Twitter when he was an ophthalmology resident in Iowa. More than 13,400 people have registered to attend the American Thoracic Society (ATS) International Conference, which is being held this weekend at the San Diego Convention Center.
Read More